Tagged with M

Switzerland As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss goods, putting pressure on Switzerland’s most important industrial sector, which is responsible for ten percent of GDP and 41 percent…

Switzerland In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies.   While much of the global narrative around the European life sciences market centres on doom and gloom (access delays for innovative medicines,…

Switzerland Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush to meet soaring market demand, and the global industry is scrambling to align with the Trump administration’s threats and incentives…

Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

France France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of France BioLead, who is leading efforts to structure the country’s ecosystem, foster collaboration, and attract sustainable investment. In this conversation,…

USA Once centred on building awareness, the Alliance for Regenerative Medicine has grown into the world’s foremost advocate for the cell and gene therapy sector, bringing together more than 400 members across biotech, pharma, academia, and patient organisations. In this conversation, CEO Timothy Hunt discusses how the field is moving from…

USA Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration is putting pressure on pharma to situate production on US soil. This pressure is predominantly taking the form of economic…

Denmark Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double the sector’s economic weight by 2030, to its sweeping “Health Closer to You” reform, biotech surge, clinical-trials strategy, and evolving…

USA Duane Barnes, President of Sobi North America, outlines how the company has rapidly expanded its presence in the region to become a key player in rare diseases, growing its US business more than twenty-fold over the past decade. He discusses Sobi’s strong focus on haematology and immunology, the company’s upcoming…

LatAm Constanza Losada, VP & General Manager for Latin America at BMS, leads one of the company’s fastest-growing regions, driving access to innovation, regional collaboration, and talent mobility. With major investments in clinical research, digital health, and cell therapy, she positions Latin America as a hub for growth and global impact…

Mexico Adriana Eguia Alaniz is President of Tijuana EDC, leading efforts to diversify and strengthen the region’s economy. Under her leadership, Tijuana has strengthened its role as a major medical device export hub, with 55,000 workers, $3B in exports, and 40+ global companies. Her priorities include cross-border speed-to-market, supply chain resilience,…